382 related articles for article (PubMed ID: 37006286)
1. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
4. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas-Unveiling Its Potential for Oncolytic Virotherapy.
Calderón-Peláez MA; Maradei Anaya SJ; Bedoya-Rodríguez IJ; González-Ipuz KG; Vera-Palacios D; Buitrago IV; Castellanos JE; Velandia-Romero ML
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675903
[TBL] [Abstract][Full Text] [Related]
5. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
6. Gospel of malignant Glioma: Oncolytic virus therapy.
Li J; Meng Q; Zhou X; Zhao H; Wang K; Niu H; Wang Y
Gene; 2022 Apr; 818():146217. PubMed ID: 35093451
[TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
10. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
11. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
14. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Shoaf ML; Desjardins A
Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
Front Immunol; 2022; 13():950079. PubMed ID: 36703982
[TBL] [Abstract][Full Text] [Related]
17. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
[TBL] [Abstract][Full Text] [Related]
18. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
Zhang Q; Liu F
Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
20. Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review.
Wang JL; Scheitler KM; Wenger NM; Elder JB
Neurosurg Focus; 2021 Feb; 50(2):E2. PubMed ID: 33524943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
